Cingulate (CING) News Today $3.95 -0.04 (-1.00%) As of 02:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CING Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Ascendiant Capital Markets Issues Positive Forecast for Cingulate (NASDAQ:CING) Stock PriceMay 28 at 1:21 AM | americanbankingnews.comWhat is Roth Capital's Estimate for Cingulate Q2 Earnings?May 22, 2025 | americanbankingnews.comEfficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHDMay 21, 2025 | finance.yahoo.comCingulate Retail Buzz Surges As ADHD Drug Shows Phase 3 Pediatric EfficacyMay 21, 2025 | msn.comCingulate receives FDA meeting feedback on ADHD drugMay 16, 2025 | uk.investing.comCING: First Quarter 2025 ResultsMay 16, 2025 | finance.yahoo.comCingulate Retail Buzz Rises After FDA Greenlights Summer NDA Filing For ADHD DrugMay 16, 2025 | msn.comFDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301May 14, 2025 | finance.yahoo.comCingulate Inc Terminates Grant Agreement with FoundationMay 13, 2025 | tipranks.comCingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety AssetsMay 8, 2025 | globenewswire.comRoth MKM Sticks to Their Buy Rating for Cingulate Inc (CING)May 3, 2025 | theglobeandmail.comWhy Some Humans Are More Likely to Help According to NeuroscienceMay 2, 2025 | msn.comType 2 diabetes alters brain circuits involved in reward processing, study findsMay 1, 2025 | msn.comCingulate Inc. Receives Buy Rating Amid Promising Developments in ADHD Treatment CTx-1301April 30, 2025 | tipranks.comCingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHDApril 29, 2025 | finance.yahoo.comCING: 2024 Financial and Operational ResultsApril 10, 2025 | msn.comCingulate secures $3m to advance once-daily anxiety treatmentApril 10, 2025 | finance.yahoo.comCingulate receives $3M grant from to accelerate development of CTx-2103April 10, 2025 | markets.businessinsider.comCingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)April 9, 2025 | globenewswire.comRoth MKM Keeps Their Buy Rating on Cingulate Inc (CING)April 5, 2025 | markets.businessinsider.comCingulate completes pre-NDA meeting with FDA on NDA for CTx-1301April 4, 2025 | markets.businessinsider.comWhy Alzheimer's Risk Increases With This Common Condition: New StudyApril 2, 2025 | msn.comRoth MKM Remains a Buy on Cingulate Inc (CING)April 1, 2025 | markets.businessinsider.comCingulate sees cash runway sufficient into Q4March 27, 2025 | markets.businessinsider.comCingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones AchievedMarch 27, 2025 | finance.yahoo.comCingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones AchievedMarch 26, 2025 | globenewswire.comRoth MKM Sticks to Its Buy Rating for Cingulate Inc (CING)March 24, 2025 | markets.businessinsider.comParts of the brain that are needed to remember words identifiedMarch 19, 2025 | msn.comCING: April Pre-NDA MeetingMarch 10, 2025 | msn.comPain and Itch Processed by Distinct Neurons in the Anterior Cingulate CortexMarch 6, 2025 | msn.comChewing wood provides sliver of hope against memory lossMarch 6, 2025 | msn.comAnalysts Offer Insights on Healthcare Companies: AMN Healthcare Services (AMN), Cingulate Inc (CING) and Veeva Systems (VEEV)March 6, 2025 | markets.businessinsider.comRoth MKM Reaffirms Their Buy Rating on Cingulate Inc (CING)March 5, 2025 | markets.businessinsider.comPromising Prospects for Cingulate Inc.: Buy Rating Backed by Positive Phase 3 Results and Market Potential of CTx-1301March 5, 2025 | tipranks.comHow the brain distinguishes between pain and itchMarch 4, 2025 | msn.comStudy provides new insights into how the brain distinguishes between pain and itchMarch 4, 2025 | msn.comCingulate reports safety results from final Phase 3 trials for CTx-1301March 4, 2025 | markets.businessinsider.comCingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025March 4, 2025 | markets.businessinsider.comCingulate Inc. Advances Towards FDA Approval for CTx-1301March 4, 2025 | tipranks.comWhat happens in your brain when there’s a word ‘on the tip of the tongue’?February 14, 2025 | msn.comWhat happens in the brain when there's a word 'on the tip of the tongue'?February 13, 2025 | msn.comCingulate CEO cleared of charges, retains board confidenceFebruary 3, 2025 | msn.comCingulate price target adjusted to $20 from $8 at H.C. WainwrightJanuary 30, 2025 | markets.businessinsider.comCingulate stock price target raised to $20 at H.C. WainwrightJanuary 30, 2025 | msn.comI Scanned A Democrat & Republican's BrainsJanuary 29, 2025 | msn.comCingulate Inc. adjusts executive compensationJanuary 25, 2025 | msn.comRoth MKM Initiates Coverage of Cingulate (CING) with Buy RecommendationJanuary 10, 2025 | msn.comCingulate Inc’s Promising Market Positioning and Accelerated Path to Market Entry for CTx-1301January 8, 2025 | markets.businessinsider.comCingulate Inc Completes Key FDA Study for ADHD DrugJanuary 7, 2025 | markets.businessinsider.comFinal Study Completed for Cingulate’s Lead Asset CTx-1301January 7, 2025 | markets.businessinsider.com Get Cingulate News Delivered to You Automatically Sign up to receive the latest news and ratings for CING and its competitors with MarketBeat's FREE daily newsletter. Email Address CING Media Mentions By Week CING Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CING News Sentiment▼0.380.88▲Average Medical News Sentiment CING News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CING Articles This Week▼43▲CING Articles Average Week Get Cingulate News Delivered to You Automatically Sign up to receive the latest news and ratings for CING and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Context Therapeutics News Today Acumen Pharmaceuticals News Today PyroGenesis Canada News Today Achilles Therapeutics News Today Metagenomi News Today ImmuCell News Today Skye Bioscience News Today Applied Therapeutics News Today vTv Therapeutics News Today Repare Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CING) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump Just Gave the Green Light to Rewrite Social Security?In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBuffett’s Next Move Could Shock Wall StreetIn just a few weeks, a move decades in the making could be revealed — and when it is, it could ignite the next...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cingulate Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cingulate With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CING Stock Free CING Stock Alerts